Congress Wealth Management LLC DE Buys New Position in Edwards Lifesciences Co. (NYSE:EW)

Congress Wealth Management LLC DE bought a new stake in Edwards Lifesciences Co. (NYSE:EWGet Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,785 shares of the medical research company’s stock, valued at approximately $749,000.

Other institutional investors have also recently made changes to their positions in the company. Capital Research Global Investors increased its position in shares of Edwards Lifesciences by 7.9% during the 3rd quarter. Capital Research Global Investors now owns 6,398,861 shares of the medical research company’s stock worth $724,418,000 after purchasing an additional 465,759 shares during the last quarter. EP Wealth Advisors LLC increased its position in shares of Edwards Lifesciences by 18.5% during the 3rd quarter. EP Wealth Advisors LLC now owns 37,608 shares of the medical research company’s stock worth $4,258,000 after purchasing an additional 5,872 shares during the last quarter. Peapack Gladstone Financial Corp increased its position in shares of Edwards Lifesciences by 18.3% during the 3rd quarter. Peapack Gladstone Financial Corp now owns 18,726 shares of the medical research company’s stock worth $2,120,000 after purchasing an additional 2,892 shares during the last quarter. Tredje AP fonden increased its position in shares of Edwards Lifesciences by 209.4% during the 3rd quarter. Tredje AP fonden now owns 82,000 shares of the medical research company’s stock worth $9,283,000 after purchasing an additional 55,500 shares during the last quarter. Finally, Dixon Hubard Feinour & Brown Inc. VA increased its position in shares of Edwards Lifesciences by 36.7% during the 4th quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 3,973 shares of the medical research company’s stock worth $515,000 after purchasing an additional 1,067 shares during the last quarter. 81.91% of the stock is currently owned by institutional investors and hedge funds.

EW has been the subject of several research analyst reports. StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday. Wolfe Research initiated coverage on Edwards Lifesciences in a research note on Tuesday, April 5th. They set an “outperform” rating and a $134.00 target price for the company. Morgan Stanley reduced their target price on Edwards Lifesciences from $148.00 to $136.00 and set an “overweight” rating for the company in a research note on Thursday, January 27th. Truist Financial began coverage on Edwards Lifesciences in a research note on Tuesday, April 12th. They issued a “buy” rating and a $145.00 price target for the company. Finally, Sanford C. Bernstein upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $132.00 to $135.00 in a research note on Wednesday, March 16th. Five research analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus target price of $127.52.

Edwards Lifesciences stock opened at $119.28 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.38 and a current ratio of 3.08. Edwards Lifesciences Co. has a 52 week low of $87.32 and a 52 week high of $131.73. The stock has a market capitalization of $74.11 billion, a P/E ratio of 49.91, a price-to-earnings-growth ratio of 3.36 and a beta of 1.15. The stock has a fifty day moving average of $112.55 and a 200-day moving average of $115.09.

Edwards Lifesciences (NYSE:EWGet Rating) last posted its quarterly earnings results on Wednesday, January 26th. The medical research company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.04). Edwards Lifesciences had a return on equity of 26.53% and a net margin of 28.73%. The business had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.34 billion. During the same period last year, the firm posted $0.50 EPS. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

In other news, VP Catherine M. Szyman sold 20,000 shares of the stock in a transaction dated Monday, April 11th. The stock was sold at an average price of $122.04, for a total value of $2,440,800.00. Following the completion of the sale, the vice president now owns 27,569 shares of the company’s stock, valued at $3,364,520.76. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 11,050 shares of the stock in a transaction dated Friday, January 28th. The shares were sold at an average price of $101.15, for a total value of $1,117,707.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 216,859 shares of company stock valued at $24,110,684. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Read More

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.